(Q34565669)

English

Impact of exposure to interferon beta-1a on outcomes in patients with relapsing-remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21339904%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Impact of exposure to interferon beta-1a on outcomes in patients with relapsing-remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up study (English)

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21339904%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

multiple sclerosis

0 references

0 references

relapsing-remitting multiple sclerosis

0 references

Cris Constantinescu

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21339904%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Anthony Traboulsee

8

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21339904%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

author name string

Bernard Uitdehaag

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21339904%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Peter Cornelisse

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21339904%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Douglas Jeffery

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21339904%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

David Li

6

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21339904%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Magnhild Sandberg-Wollheim

7

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21339904%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Elisabetta Verdun

9

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21339904%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Victor Rivera

10

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21339904%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Ludwig Kappos

5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21339904%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

publication date

1 January 2011

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21339904%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Therapeutic advances in neurological disorders

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21339904%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21339904%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21339904%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

3-14

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21339904%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3036958

7 July 2018

Measuring adherence and persistence to disease-modifying agents among patients with relapsing remitting multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3036958

7 July 2018

Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3036958

7 July 2018

Efficacy of disease-modifying therapies in relapsing remitting multiple sclerosis: a systematic comparison

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3036958

7 July 2018

Integrating an evidence-based assessment of benefit and risk in disease-modifying treatment of multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3036958

7 July 2018

Early MS treatment.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3036958

7 July 2018

Diagnosis and treatment of multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3036958

7 July 2018

The importance of maintaining effective therapy in multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3036958

7 July 2018

Multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3036958

7 July 2018

Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study.

1 reference

https://api.crossref.org/works/10.1177%2F1756285610391693

21 January 2018

Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.

1 reference

https://api.crossref.org/works/10.1177%2F1756285610391693

21 January 2018

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

1 reference

https://api.crossref.org/works/10.1177%2F1756285610391693

21 January 2018

Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial

1 reference

https://api.crossref.org/works/10.1177%2F1756285610391693

21 January 2018

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1756285610391693

21 January 2018

Relapse, remission, and progression in multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/21339904

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/21339904

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/21339904

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/21339904

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/21339904

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prospective assessment of changing from placebo to IFN beta-1a in relapsing MS: the PRISMS study

1 reference

https://pubmed.ncbi.nlm.nih.gov/21339904

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose, high-frequency recombinant interferon beta-1a in the treatment of multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/21339904

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: A multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon β-1a for re

1 reference

https://pubmed.ncbi.nlm.nih.gov/21339904

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1177/1756285610391693

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21339904%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21339904%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21339904%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34565669&oldid=1408399893"